SAUDI ARABIA Trends and Developments Contributed by: Dr Saud Alromi, Mostafa Ihab, Mohamed Ramadan and Saleh Albadry, Mohammed Al Dhabaan & Partners Eversheds Sutherland
ment and fund future research. The SAIP also plays a crucial role in enforcing IP rights, tak - ing legal action against infringers and ensuring that counterfeit products are removed from the market. Pricing rules The SFDA has detailed rules for pricing pharma - ceutical products, taking various factors such as therapeutic value, prices of alternatives, and economic studies into account. Key points include the following. Innovative and biological products Innovative and biological products are priced based on export prices and comparative stud - ies. Generic products Generic products are priced at a percentage of the innovative product’s price, with reductions as more generics enter the market. Re-pricing Products may be re-priced based on market conditions, therapeutic class reviews, and com - pany requests. The SFDA guidelines The SFDA has established comprehensive guide - lines for the submission, validation, assessment, and pricing of pharmaceutical products. These guidelines ensure drug safety, efficacy, and qual - ity through stringent pharmacovigilance meas - ures. Key aspects include the following. Bioequivalence studies Bioequivalence studies are required for generic drugs to ensure they meet safety and efficacy standards.
Clinical trials Clinical trials are necessary for vaccines to ensure their effectiveness and safety. Submission process The submission process involves online submis - sion, technical and business validation, evalua - tion/inspection, and pricing review. Key Players in the Saudi Arabian Healthcare Sector Several key entities play significant roles in the Saudi Arabian healthcare sector. They are as fol - lows. The Ministry of Health (MoH) The MoH regulates all healthcare-related activi - ties and services within the country. It also over - sees the implementation of healthcare policies, ensures compliance with regulatory standards, and works to improve the quality of healthcare services. Additionally, it is responsible for launch - ing health clusters and integrating healthcare provider networks that aim to improve access to healthcare services and promote preventive care. The National Unified Company for Medical Supplies (NUPCO) NUPCO is responsible for centralised govern - ment procurement of pharmaceuticals, medical equipment, and supplies. It collects require - ments from government agencies, issues tenders, and manages the supply chain and logistics for public healthcare facilities. This cen - tralised approach ensures that public healthcare providers have access to the necessary medical supplies and pharmaceuticals.
271 CHAMBERS.COM
Powered by FlippingBook